Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more attracti

Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term

10:46am, Tuesday, 03'rd Jun 2025

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Does Catalyst (CPRX) Have the Potential to Rally 36.22% as Wall Street Analysts Expect?

11:01am, Monday, 02'nd Jun 2025

The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the posit

Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

10:46am, Monday, 02'nd Jun 2025

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Catalyst (CPRX) Is a Great Choice for 'Trend' Investors, Here's Why

09:56am, Monday, 02'nd Jun 2025

Catalyst (CPRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

08:03am, Monday, 02'nd Jun 2025

Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career

Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma

05:18am, Saturday, 31'st May 2025

FIRDAPSE continues to drive strong performance, with Q1 2025 revenue and EPS both beating analyst expectations significantly. Catalyst reaffirmed its 2025 FIRDAPSE revenue guidance of $355–$360 mill

Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript

12:02pm, Thursday, 08'th May 2025

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Dal

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y

12:00pm, Thursday, 08'th May 2025

CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.

Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key Metrics

08:05pm, Wednesday, 07'th May 2025

The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat

Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates

07:31pm, Wednesday, 07'th May 2025

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago.

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

04:14pm, Wednesday, 07'th May 2025

Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sus

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by